

Resource Summary Report

Generated by [dkNET](#) on Aug 5, 2026

TIM-3 (D5D5R™) XP® Rabbit mAb

RRID:AB_2716862

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 45208, RRID:AB_2716862

Antibody Information

URL: http://antibodyregistry.org/AB_2716862

Proper Citation: Cell Signaling Technology Cat# 45208, RRID:AB_2716862

Target Antigen: TIM-3

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IP, IHC-Bond, IHC-P, F
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: TIM-3 (D5D5R™) XP® Rabbit mAb

Description: This recombinant monoclonal targets TIM-3

Target Organism: human

Clone ID: D5D5R™

Antibody ID: AB_2716862

Vendor: Cell Signaling Technology

Catalog Number: 45208

Record Creation Time: 20250820T000950+0000

Record Last Update: 20250820T073214+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for TIM-3 (D5D5R™) XP® Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liu HM, et al. (2025) Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. Cell reports. Medicine, 6(2), 101930.

Zhu B, et al. (2025) Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer cell, 43(6), 1125.

Digomann D, et al. (2025) Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. iScience, 28(11), 113871.

Liu F, et al. (2025) Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization. Cell genomics, 5(7), 100888.

Quek C, et al. (2024) Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell reports, 43(7), 114392.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer cell, 42(1), 135.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell reports. Medicine, 5(2), 101397.

Wang Y, et al. (2023) Intratumoral erythroblastic islands restrain anti-tumor immunity in hepatoblastoma. Cell reports. Medicine, 4(5), 101044.

Wang Z, et al. (2023) Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. Cell metabolism, 35(7), 1209.

Ausejo-Mauleon I, et al. (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. *Cancer cell*, 41(11), 1911.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8⁺ T cell exhaustion via TRIM14-IFN- γ axis. *Cell reports*, 42(8), 112944.

Guo Q, et al. (2022) Cancer cell intrinsic TIM-3 induces glioblastoma progression. *iScience*, 25(11), 105329.

Li K, et al. (2022) Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. *Cancer cell*, 40(11), 1374.

Wingrove E, et al. (2019) Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. *Cell reports*, 27(4), 1277.

de Mingo Pulido Á, et al. (2018) TIM-3 Regulates CD103⁺ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. *Cancer cell*, 33(1), 60.